JPWO2024150525A1 - - Google Patents
Info
- Publication number
- JPWO2024150525A1 JPWO2024150525A1 JP2024570056A JP2024570056A JPWO2024150525A1 JP WO2024150525 A1 JPWO2024150525 A1 JP WO2024150525A1 JP 2024570056 A JP2024570056 A JP 2024570056A JP 2024570056 A JP2024570056 A JP 2024570056A JP WO2024150525 A1 JPWO2024150525 A1 JP WO2024150525A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003133 | 2023-01-12 | ||
| PCT/JP2023/041176 WO2024150525A1 (ja) | 2023-01-12 | 2023-11-16 | 抗ネコｐｄ－１抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2024150525A1 true JPWO2024150525A1 (https=) | 2024-07-18 |
Family
ID=91896741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024570056A Pending JPWO2024150525A1 (https=) | 2023-01-12 | 2023-11-16 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4650450A1 (https=) |
| JP (1) | JPWO2024150525A1 (https=) |
| WO (1) | WO2024150525A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026038455A1 (ja) * | 2024-08-14 | 2026-02-19 | 国立大学法人山口大学 | 細胞傷害活性及び細胞貪食活性を低減させた抗ネコ抗体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| FR2741066B1 (fr) | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2743365A1 (fr) | 1996-01-10 | 1997-07-11 | Rhone Poulenc Rorer Sa | Derives de 5h,10h-imidazo(1,2-a)indolo(3,2-e)pyrazine-4-one, leur preparation et les medicaments les contenant |
| DE19605548A1 (de) | 1996-02-15 | 1997-09-04 | Boehringer Ingelheim Int | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
| DE19607686A1 (de) | 1996-02-29 | 1997-09-04 | Chemicon Lab Gmbh | Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US10280223B2 (en) | 2014-07-09 | 2019-05-07 | Nippon Zenyaku Kogyo Co., Ltd. | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
| SG11202105153RA (en) * | 2018-11-19 | 2021-06-29 | Biocytogen Pharmaceuticals Beijing Co Ltd | Anti-pd-1 antibodies and uses thereof |
-
2023
- 2023-11-16 EP EP23915192.1A patent/EP4650450A1/en active Pending
- 2023-11-16 JP JP2024570056A patent/JPWO2024150525A1/ja active Pending
- 2023-11-16 WO PCT/JP2023/041176 patent/WO2024150525A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4650450A1 (en) | 2025-11-19 |
| WO2024150525A1 (ja) | 2024-07-18 |